A recent study published in Nature Machine Intelligence examines a novel deep-learning method known as BigMHC, which can predict when the immune system will respond to triggers from cancer-related protein fragments, thus killing the tumors. This study was led and conducted by a team of researchers at Johns Hopkins University and holds the potential to develop personalized cancer immunotherapies and vaccines.
Rendition of cytotoxic CD8+ T-cells identifying cancer cells via receptor binding neoantigens. (Credit: Image generated by DALL-E 2 from OpenAI)
“Cancer immunotherapy is designed to activate a patient’s immune system to destroy cancer cells,” said Dr. Rachel Karchin, who is a professor of biomedical engineering, oncology and computer science at Johns Hopkins University, and a co-author on the study. “A critical step in the process is immune system recognition of cancer cells through T-cell binding to cancer-specific protein fragments on the cell surface.”
Leave a reply